Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) EBIT (2019 - 2025)

Historic EBIT for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$265689.0.

  • Bioadaptives' EBIT fell 11788.32% to -$265689.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 24648.51%. This contributed to the annual value of -$602090.0 for FY2024, which is 16301.21% down from last year.
  • As of Q3 2025, Bioadaptives' EBIT stood at -$265689.0, which was down 11788.32% from -$279219.0 recorded in Q2 2025.
  • In the past 5 years, Bioadaptives' EBIT registered a high of -$18975.0 during Q1 2023, and its lowest value of -$337339.0 during Q4 2024.
  • For the 5-year period, Bioadaptives' EBIT averaged around -$141213.1, with its median value being -$121941.0 (2024).
  • Per our database at Business Quant, Bioadaptives' EBIT tumbled by 89704.93% in 2021 and then skyrocketed by 8911.08% in 2023.
  • Over the past 5 years, Bioadaptives' EBIT (Quarter) stood at -$177734.0 in 2021, then soared by 84.64% to -$27302.0 in 2022, then tumbled by 126.3% to -$61784.0 in 2023, then crashed by 446.0% to -$337339.0 in 2024, then rose by 21.24% to -$265689.0 in 2025.
  • Its EBIT stands at -$265689.0 for Q3 2025, versus -$279219.0 for Q2 2025 and -$249148.0 for Q1 2025.